Robert Dreicer, MD, describes the future of metastatic castration-resistant prostate cancer.
Imaging advancements in ccRCC are crucial for predicting tumor biology and enhancing treatment strategies through molecular imaging techniques.
Drs Bechis and Semins discuss future developments in urinary stone management, emphasizing the potential for improved vacuum aspiration devices, combined intravenous and PCNL surgeries, and the hope for medications to dissolve stones.
"We are trying to develop epigenetic biomarkers that can predict patients that are starting to progress to neuroendocrine prostate cancer," says Jindan Yu, MD, PhD.
"Just having someone with another set of eyes I think is always helpful and gives you a lot of inspiration as well as a lot of encouragement on exactly what you need to do next," says Gia Ching.
Neal Shore, MD, FACS, is a U.S. Chief Medical Officer at GenesisCare USA and Medical Director of the Carolina Urologic Research Center. He also was an investigator on the Phase 2 and 3 studies in the clinical trial program for nadofaragene firadenovec-vncg.
Panelists discuss the characteristics of an ideal multidisciplinary team for managing BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC), emphasizing the need for oncologists and urologists to collaboratively prepare for successful patient outcomes across different markets, while also identifying necessary educational resources and highlighting adverse events that require attention in preparation for product launches.
"We see that among the patients who went on to receiving cystectomy, 84% are metastases free," says Pooja Ghatalia, MD.
"RPLND is an attractive option for those who prefer to avoid chemotherapy," write Jiping Zeng, MD; Timothy A. Masterson, MD; and Clint Cary, MD, MPH, MBA.
Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Kelvin Moses, MD, PhD, interviews Tracy M. Downs, MD, about progress and remaining challenges regarding diversity, equity, and inclusion in the field of urology.
A prostate cancer expert breaks down likelihood of a diagnosis of metastatic prostate cancer and touches on available treatment options.
“This is another therapeutic that adds to UroGen [profile] as a potential treatment that could be used to preserve kidneys while treating low grade upper tract urothelial carcinoma going forward,” says Sarah P. Psutka, MD, MSc.
"This brief review captures the evolving role of miRNAs, focusing on their clinical relevance and implications as well as future directions for more effective targeted therapeutic interventions," write the authors.
APPs can help in introducing genetic testing and in the interpretation of results, according to Kara Cossis, PA-C, MPH.
Grace Khaner and Melissa A. Laudano, MD, share their thoughts on the potential for expanding the use of vibegron early in treatment for OAB.
“Things we have control over are ourselves, our care team, and to some extent, our care model,” said Sarah Candler, MD.
"I would basically look at these 3 things as the major things to be coming up," says Jitesh Dhingra, MD, FRCEM.
Lutetium Lu 177 vipivotide tetraxetan improved rPFS vs switching to abiraterone acetate or enzalutamide in patients with taxane-naïve mCRPC who had progressed on prior abiraterone or enzalutamide. Outcomes were better, however, in patients who initially received abiraterone.
"The notion that the urine is sterile should be hopefully abolished by now, especially in this group where we know that these individuals do have a lot of bacteria growing in their bladders," says Brendan T. Frainey, MD.
"I think the highlights are the functional outcomes after a salvage focal ablation are favorable, definitely, compared to salvage radical prostatectomy, but the studies are quite limited in terms of real salvage focal ablation," says Kara L. Watts, MD.
"RPLND is an attractive option for those who prefer to avoid chemotherapy," write Jiping Zeng, MD; Timothy A. Masterson, MD; and Clint Cary, MD, MPH, MBA.
Neal Shore, MD, FACS, and Brian Shuch, MD, provide closing thoughts on the potential of PET/CT imaging to improve patient care in kidney cancer.
A urologist practicing in California defines the remaining general and region-specific challenges he faces in managing his practice and his hopes for future solutions.
Panelists discuss how they approach a typical bladder cancer case of a 79-year-old man with hematuria, including initial diagnostic procedures, the importance of proper tumor measurement during resection, BCG therapy protocols, and management options for BCG-unresponsive disease with a focus on nadofaragene firadenovec (Adstiladrin).
Panelists discuss how pembrolizumab, a PD-1 inhibitor, offers a systemic immunotherapy option for high-risk, BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) by enhancing the immune system’s ability to target cancer cells, with intravenous administration and careful monitoring for immune-related adverse effects.
Panelists discuss how managing cognitive and sexual health in prostate cancer patients undergoing hormonal therapy is crucial, emphasizing the need for proactive communication and tailored interventions to enhance overall quality of life.
Experts summarize how the use of PSMA-PET imaging has impacted the field to date and share their hopes for the future.
"We have communicated with Solventum, who makes this software, and they have made changes based on our feedback," says Timothy D. Lyon, MD.
Experts Naveen Kella, MD, and Dr. Shadi Esfahani, MD, MPH, consider the continued impact of PSMA PET imaging on prostate cancer management and emerging modalities that could revolutionize patient care.